Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Filings indexed 259 across all filing types
Latest filing 2025-06-12 Director's Dealing
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-06-12 English
FORM 4
Director's Dealing
2025-06-06 English
FORM 4
Director's Dealing
2025-06-06 English
FORM 4
Director's Dealing
2025-06-06 English
FORM 4
Director's Dealing
2025-06-06 English
FORM 4
Director's Dealing
2025-06-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.